Search
Lucid Diagnostics Inc
LUCDAdd to Watchlist
1.070USD
+0.020+1.90%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
176.42MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-02The current earnings forecast score of Lucid Diagnostics Inc is 8.40, ranking 38 out of 204 in the Healthcare Equipment & Supplies industry. The average price target is 3.00, with a high of 8.00 and a low of 2.50.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
3.950
Target Price
+276.19%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
117
Total
6
Median
9
Average
Company name
Ratings
Analysts
Lucid Diagnostics Inc
LUCD
5
Medtronic PLC
MDT
34
Dexcom Inc
DXCM
32
Zimmer Biomet Holdings Inc
ZBH
31
Stryker Corp
SYK
31
Abbott Laboratories
ABT
30
1
2
3
...
24
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Lucid Diagnostics Inc's expected revenue for the next quarter?
Lucid Diagnostics Inc's expected revenue is 1.44M.
What is Lucid Diagnostics Inc's price target?
Analysts forecast that Lucid Diagnostics Inc's price target is USD 3.00, with the highest forecast at USD 8.00 and the lowest forecast at USD 2.50.
How have Lucid Diagnostics IncLUCD's recent earnings per share performed?
The market expectation was USD -0.17, while Lucid Diagnostics IncLUCD's earnings per share (EPS) for the previous quarter was USD -0.12. EPS for the next quarter is expected at USD -0.07.
What is the analyst rating for Lucid Diagnostics Inc?
Based on the ratings of Lucid Diagnostics Inc's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.